Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer-Reference-Cited by-同舟云学术

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer

Published:2011-06-29 Issue:1 Volume:118 Page:241-247
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Llombart-Cussac Antonio,Ruiz Amparo,Antón Antonio,Barnadas Agustí,Antolín Silvia,Alés-Martínez José E.,Álvarez Isabel,Andrés Raquel,García Saenz José A.,Lao Juan,Carrasco Eva,Cámara Carmen,Casas Isabel,Martín Miguel

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. Is breast cancer survival improving?;Giordano;Cancer.,2004

2. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer;Chia;Cancer.,2007

3. Does survival increase in metastatic breast cancer with recently available anticancer drugs?;Abrial;Oncol Res.,2006

4. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis;Mauri;J Natl Cancer Inst.,2006

5. Aromatase and its inhibitors;Brodie;J Steroid Biochem Mol Biol.,1999

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence;Advances in Therapy;2022-01-06

2. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies;Current Oncology;2021-11-21

3. Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors;European Journal of Medicinal Chemistry;2020-12

4. Expanding Treatment Arsenal for Oestrogen Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer;Hong Kong Journal of Radiology;2019-07-08

5. Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer;Breast Cancer Research and Treatment;2019-05-07